Molecular crosstalk between apoptosis and autophagy induced by a novel 2-methoxyestradiol analogue in cervical adenocarcinoma cells

Cancer Cell International

Volumn 13, Issue 1, 2013, Pages

  Theron, Anne E ^a   Nolte, Elsie M ^a   Lafanechère, Laurence ^b   Joubert, Annie M ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b UNIV GRENOBLE ALPES   (France)

Author keywords

2 ethyl 3 O sulphamoyl estra 1,3,5(10)16 tetraene; 2 methoxyestradiol; Analogue; Apoptosis; Autophagy; Caspase; Crosstalk; ESE 16; Microtubules; Mitotic block

Indexed keywords

2 ETHYL 3 O SULPHAMOYL ESTRA 1,3,5 (10) 16 TETRAENE; 2 METHOXYESTRADIOL; CASPASE 3; CASPASE 8; CYCLIN B1; MICROTUBULE ASSOCIATED PROTEIN; MICROTUBULE ASSOCIATED PROTEIN LIGHT CHAIN 3; PHOSPHATIDYLSERINE; UNCLASSIFIED DRUG;

AGGRESOME; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL CYCLE CHECKPOINT; CELL CYCLE PROGRESSION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME INDUCTION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; METAPHASE; MICROTUBULE; MOLECULAR INTERACTION; PHASE CONTRAST MICROSCOPY; QUANTITATIVE ANALYSIS; SPECTROPHOTOMETRY; TRANSMISSION ELECTRON MICROSCOPY;

EID: 84883076943     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-13-87     Document Type: Article

References (53)

1. Matei D, Schilder J, Sutton G, Perkins S, Breen T, Quon C, Sidor C. Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Gynecol Oncol 2009, 115(1):90-96. 10.1016/j.ygyno.2009.05.042, 19577796.
2. Mooberry SL. Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Update 2003, 6(6):355-361.
3. Tevaarwerk AJ, Holen KD, Alberti DB, Sidor C, Arnott J, Quon C, Wilding G, Liu G. Phase I trial of 2-methoxyestradiol Nano crystal dispersion in advanced solid malignancies. Clin Cancer Res 2009, 15(4):1460-1465. 10.1158/1078-0432.CCR-08-1599, 2892631, 19228747.
4. Dubey RK, Jackson EK. Potential vascular actions of 2-methoxyestradiol. Trends Endocrinol Metab 2009, 20(8):374-379. 10.1016/j.tem.2009.04.007, 2761235, 19734053.
5. Kato S, Sadarangani A, Lange S, Delpiano AM, Vargas M, Brañes J, Carvajal J, Lipkowitz S, Owen GI, Cuello MA. 2-Methoxyestradiol mediates apoptosis through caspase-dependent and independent mechanisms in ovarian cancer cells but not in normal counterparts. Reprod Sci 2008, 15(9):878-894. 10.1177/1933719108324171, 19050321.
6. Stander BA, Marais S, Vorster CJ, Joubert AM. In vitro effects of 2-methoxyestradiol on morphology, cell cycle progression, cell death and gene expression changes in the tumorigenic MCF-7 breast epithelial cell line. J Steroid Biochem Mol Biol 2010, 119(3-5):149-160.
7. Amorino GP, Freeman ML, Choy H. Enhancement of radiation effects in vitro by the estrogen metabolite 2-methoxyestradiol. Radiat Res 2000, 153(4):384-391. 10.1667/0033-7587(2000)153[0384:EOREIV]2.0.CO;2, 10760997.
8. Han G-Z, Liu Z-J, Shimoi K, Zhu BT. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer. Cancer Res 2005, 65(2):387-393.
9. Van Zijl C, Lottering ML, Steffens F, Joubert A. In vitro effects of 2-methoxyestradiol on MCF-12A and MCF-7 cell growth, morphology and mitotic spindle formation. Cell Biochem Funct 2008, 26(5):632-642. 10.1002/cbf.1489, 18508385.
10. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994, 368(6468):237-239. 10.1038/368237a0, 7511798.
11. Newman SP, Ireson CR, Tutill HJ, Day JM, Parsons MFC, Leese MP, Potter BVL, Reed MJ, Purohit A. The role of 17β-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cells. Cancer Res 2006, 66(1):324-330. 10.1158/0008-5472.CAN-05-2391, 16397246.
12. Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, Fife K, Armstrong V, Treston A, Sidor C, et al. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res 2005, 11(18):6625-6633. 10.1158/1078-0432.CCR-05-0440, 16166441.
13. Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 2005, 227(2):115-124. 10.1016/j.canlet.2004.10.007, 16112414.
14. Du B, Li Y, Li X, AY, Chen C, Zhang Z. Preparation, characterization and in vivo evaluation of 2-methoxyestradiol-loaded liposomes. Int J Pharm 2010, 384(1-2):140-147.
15. Visagie MH, Joubert AM. In vitro effects of 2-methoxyestradiol-bis-sulphamate on reactive oxygen species and possible apoptosis induction in a breast adenocarcinoma cell line. Cancer Cell Int 2011, 11(1):43. 10.1186/1475-2867-11-43, 3251537, 22152028.
16. Pasquier E, Sinnappan S, Munoz MA, Kavallaris M. ENMD-1198, a New Analogue of 2-Methoxyestradiol, Displays Both Antiangiogenic and Vascular-Disrupting Properties. Mol Cancer Ther 2010, 9(5):1408-1418. 10.1158/1535-7163.MCT-09-0894, 20442304.
17. Stander XX, Stander BA, Joubert AM. In vitro effects of an in silico-modelled 17β-estradiol derivative in combination with dichloroacetic acid on MCF-7 and MCF-12A cells. Cell Prolif 2011, 44(6):567-581. 10.1111/j.1365-2184.2011.00789.x, 21992416.
18. Marais S, Mqoco T, Stander A, van Papendorp D, Joubert A. The in vitro effects of a sulphamoylated derivative of 2-methoxyestradiol on cell number, morphology and alpha-Tubulin disruption in cervical adenocarcinoma (HeLa) cells. Biomed Res 2012, 23(3):357-362.
19. Tinley TL, Leal RM, Randall-Hlubek DA, Cessac JW, Wilkens LR, Rao PN, Mooberry SL. Novel 2-methoxyestradiol analogues with antitumor activity. Cancer Res 2003, 63(7):1538-1549.
20. Cushman M, He HM, Katzenellenbogen JA, Lin CM, Hamel E. Synthesis, anti-Tubulin and anti-mitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of Estradiol that inhibits Tubulin polymerization by binding to the colchicine binding site. J Med Chem 1995, 38(12):2041-2049. 10.1021/jm00012a003, 7783135.
21. Leese MP, Newman SP, Purohit A, Reed MJ, Potter BV. 2-Alkylsulfanyl estrogen derivatives: synthesis of a novel class of multi-targeted anti-tumour agents. Bioorg Med Chem Lett 2004, 14(12):3135-3138. 10.1016/j.bmcl.2004.04.027, 15149660.
22. LaVallee TM, Burke PA, Swartz GM, Hamel E, Agoston GE, Shah J, Suwandi L, Hanson AD, Fogler WE, Sidor CF, et al. Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. Mol Cancer Ther 2008, 7(6):1472-1482. 10.1158/1535-7163.MCT-08-0107, 18566218.
23. Edsall AB, Mohanakrishnan AK, Yang D, Fanwick PE, Hamel E, Hanson AD, Agoston GE, Cushman M. Effects of altering the electronics of 2-methoxyestradiol on cell proliferation, on cytotoxicity in human cancer cell cultures, and on Tubulin polymerization. J Med Chem 2004, 47(21):5126-5139. 10.1021/jm049647a, 15456256.
24. Elger W, Schwarz S, Hedden A, Reddersen G, Schneider B. Sulfamates of various estrogens are pro-drugs with increased systemic and reduced hepatic estrogenicity at oral application. J Steroid Biochem Mol Biol 1995, 55(3-4):395-403.
25. Ho YT, Purohit A, Vicker N, Newman SP, Robinson JJ, Leese MP, Ganeshapillai D, Woo LWL, Potter BVL, Reed MJ. Inhibition of carbonic anhydrase II by steroidal and non-steroidal sulphamates. Biochem Biophys Res Commun 2003, 305(4):909-914. 10.1016/S0006-291X(03)00865-9, 12767917.
26. Pastorekova S, Ratcliffe PJ, Pastorek J. Molecular mechanisms of carbonic anhydrase IX-mediated pH regulation under hypoxia. BJU Int 2008, 101(Suppl 4):8-15.
27. Chiche J, Ilc K, Laferrière J, Trottier E, Dayan F, Mazure NM, Brahimi-Horn MC, Pouysségur J. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 2009, 69(1):358-368. 10.1158/0008-5472.CAN-08-2470, 19118021.
28. Stubbs M, McSheehy PM, Griffiths JR, Bashford CL. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today 2000, 6(1):15-19. 10.1016/S1357-4310(99)01615-9, 10637570.
29. Leese MP, Leblond B, Smith A, Newman SP, Di Fiore A, De Simone G, Supuran CT, Purohit A, Reed MJ, Potter BV. 2-substituted Estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem 2006, 49(26):7683-7696. 10.1021/jm060705x, 17181151.
30. Elger W, Barth A, Hedden A, Reddersen G, Ritter P, Schneider B, Züchner J, Krahl E, Müller K, Oettel M, Schwarz S. Estrogen sulfamates: a new approach to oral estrogen therapy. Reprod Fertil Dev 2001, 13(4):297-305. 10.1071/RD01029, 11800168.
31. Vorster C, Joubert A. In vitro effects of 2-methoxyestradiol-bis-sulphamate on cell growth, morphology and cell cycle dynamics in the MCF-7 breast adenocarcinoma cell line. Biocell 2010, 34(2):71-79.
32. Ireson CR, Chander SK, Purohit A, Perera S, Newman SP, Parish D, Leese MP, Smith AC, Potter BV, Reed MJ. Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. Br J Cancer 2004, 90(4):932-937. 10.1038/sj.bjc.6601591, 2410173, 14970876.
33. Stander A, Joubert F, Joubert A. Docking, synthesis, and in vitro evaluation of antimitotic Estrone analogs. Chem Biol Drug Des 2011, 77(3):173-181. 10.1111/j.1747-0285.2010.01064.x, 21244635.
34. Miyazaki T, Arai S. Two distinct controls of mitotic Cdk1/Cyclin B1 activity requisite for cell growth prior to cell division. Cell Cycle 2007, 6(12):1418-1424.
35. Boucrot E, Kirchhausen T. Mammalian cells change volume during mitosis. PLoS ONE 2008, 3(1):e1477. 10.1371/journal.pone.0001477, 2198941, 18213385.
36. Laane E, Tamm KP, Buentke E, Ito K, Khahariza P, Oscarsson J, Corcoran M, Bjorklund AC, Hultenby K, Lundin J, et al. Cell death induced by Dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ 2009, 16(7):1018-1029. 10.1038/cdd.2009.46, 19390558.
37. Thaver V, Lottering ML, van Papendorp D, Joubert A. In vitro effects of 2-methoxyestradiol on cell numbers, morphology, cell cycle progression, and apoptosis induction in oesophageal carcinoma cells. Cell Biochem Funct 2009, 27(4):205-210. 10.1002/cbf.1557, 19343733.
38. Li L, Bu S, Backstrom T, Landstrom M, Ulmsten U, Fu X. Induction of apoptosis and G2/M arrest by 2-methoxyestradiol in human cervical cancer HeLaS3 cells. Anticancer Res 2004, 24(2B):873-880.
39. Androic I, Kramer A, Yan R, Rodel F, Gatje R, Kaufmann M, Strebhardt K, Yuan J. Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol. BMC Cancer 2008, 8(1):391. 10.1186/1471-2407-8-391, 2639606, 19113992.
40. Matson DR, Stukenberg PT. Spindle poisons and cell fate: a tale of two pathways. Mol Interv 2011, 11(2):141-150. 10.1124/mi.11.2.12, 3086919, 21540474.
41. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, et al. Sensitivity to anti-Tubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011, 471(7336):110-114. 10.1038/nature09779, 21368834.
42. Newman SP, Foster PA, Stengel C, Day JM, Ho YT, Judde J-G, Lassalle M, Prevost G, Leese MP, Potter BVL, et al. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells. Clin Cancer Res 2008, 14(2):597-606. 10.1158/1078-0432.CCR-07-1717, 18223236.
43. Huang H-C, Shi J, Orth JD, Mitchison TJ. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 2009, 16(4):347-358. 10.1016/j.ccr.2009.08.020, 2758291, 19800579.
44. LaVallee TM, Zhan XH, Johnson MS, Herbstritt CJ, Swartz G, Williams MS, Hembrough WA, Green SJ, Pribluda VS. 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 2003, 63(2):468-475.
45. Ola M, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem 2011, 351(1):41-58.
46. Kadowaki M, Karim MR, Carpi A, Miotto G. Nutrient control of macro-autophagy in mammalian cells. Mol Aspects Med 2006, 27(5-6):426-443.
47. Djavaheri-Mergny M, Maiuri MC, Kroemer G. Cross talk between apoptosis and autophagy by caspase-mediated cleavage of Beclin 1. Oncogene 2010, 29(12):1717-1719. 10.1038/onc.2009.519, 20101204.
48. Maiuri MC, Zalckvar E, Kimchi A, Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007, 8(9):741-752. 10.1038/nrm2239, 17717517.
49. Xie Z, Klionsky DJ. Autophagosome formation: core machinery and adaptations. Nat Cell Biol 2007, 9(10):1102-1109. 10.1038/ncb1007-1102, 17909521.
50. Wirawan E, Vande Walle L, Kersse K, Cornelis S, Claerhout S, Vanoverberghe I, Roelandt R, De Rycke R, Verspurten J, Declercq W, et al. Caspase-mediated cleavage of Beclin-1 inactivates Beclin-1-induced autophagy and enhances apoptosis by promoting the release of proapoptotic factors from mitochondria. Cell Death Dis 2010, 1(1):e18. 10.1038/cddis.2009.16, 3032505, 21364619.
51. Cho DH, Jo YK, Hwang JJ, Lee YM, Roh SA, Kim JC. Caspase-mediated cleavage of ATG6/Beclin-1 links apoptosis to autophagy in HeLa cells. Cancer Lett 2009, 274(1):95-100. 10.1016/j.canlet.2008.09.004, 18842334.
52. Luo S, Rubinsztein DC. Apoptosis blocks Beclin 1-dependent autophagosome synthesis: an effect rescued by Bcl-xL. Cell Death Differ 2010, 17(2):268-277. 10.1038/cdd.2009.121, 2894406, 19713971.
53. Betin VMS, Lane JD. Caspase cleavage of Atg4D stimulates GABARAP-L1 processing and triggers mitochondrial targeting and apoptosis. J Cell Sci 2009, 122(14):2554-2566. 10.1242/jcs.046250, 2704886, 19549685.